Dear Dr. Zhu:

Please refer to your supplemental biologics license applications (sBLAs) dated and received December 5, 2014, June 24, 2015, and June 6, 2019, and your amendments, submitted under section 351(a) of the Public Health Service Act for Orencia (abatacept).

We also refer to our approval letter dated June 17, 2020, which contained the following error: Incorrect reference to Medication Guide and Adverse Reactions Section 6.6.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain June 17, 2020, the date of the original approval letter.

“Prior Approval” labeling supplement S-194 provides for conversion of Adverse Events to Adverse Reactions in Sections 6.1 and 6.2 as requested by the Agency in 2008, amendments to the safety information to update systemic injection reactions in Section 6.4, and the addition of new information regarding vaccinations in Warnings and Precautions Section 5.4.

“Changes Being Effected” labeling supplement S-199 provides for the addition of new language in Use in Specific Populations Section 8.4 as recommended by the Agency regarding administration of live vaccines to infants exposed to abatacept in utero and the addition of new language in the Patient Information labeling to advise patients to speak to their healthcare provider before vaccinating infants born to mothers treated with ORENCIA.

“Prior Approval” labeling supplement S-225 provides for the addition of skin cancer information and recommendation for periodic skin examination in the Warnings and Precautions Section 5.6, adding non-melanoma skin cancer (NMSC) as an adverse reaction reported postapproval in the Adverse Reactions Section 6.4, and adding skin

---

1 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
cancer information and recommendation for patients to inform their doctor if they have a family history of skin cancer, or changes of their skin in the Patient Information labeling.

**APPROVAL & LABELING**

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,² that is identical to the enclosed labeling (text for the Prescribing Information, Patient Information, and Instructions for Use) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As.*³

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration


³ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS
We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Colette Jackson, Senior Regulatory Health Project Manager, at (301) 796-1230.

Sincerely,

{See appended electronic signature page}

Nikolay Nikolov, M.D.
Director (Acting)
Division of Rheumatology and Transplant Medicine
Office of Immunology and Inflammation (OII)
Center for Drug Evaluation and Research

ENCLOSURES:
- Content of Labeling
  - Prescribing Information
  - Patient Information
  - Instructions for Use
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NIKOLAY P NIKOLOV
06/17/2020 12:00:00 AM